Premium
Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp Inhibition
Author(s) -
Chu Xiaoyan,
Galetin Aleksandra,
ZamekGliszczynski Maciej J.,
Zhang Lei,
Tweedie Donald J.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1213
Subject(s) - digoxin , dabigatran , pharmacology , medicine , chemistry , warfarin , atrial fibrillation , heart failure
Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth, New Jersey, USA; Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, UK; Quantitative Drug Disposition, GlaxoSmithKline plc, King of Prussia, Pennsylvania, USA; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Correspondence: Xiaoyan Chu (xiaoyan_chu@merck.com) COMMENTARY
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom